Although data with mouse-double-minute-2 (MDM2) inhibitors in combination with chemotherapies or venetoclax have shown limited clinical activity in the setting of overt relapsed disease, renewed interest has been generated for its potential in the post-transplant setting based on preclinical data suggesting MDM2 inhibition increased TRAIL-receptor-1 and -2 MHC-II expression on leukemia cells (198, 199). This evidence concerns the gene MDM2 and leukemia.